WilmerHale represented the underwriters in the public offering of Disc Medicine, Inc. of 4,533,182 shares of common stock, reflecting the full exercise of the underwriters’ option to purchase 615,000 additional shares, and 181,818 pre-funded warrants to purchase shares of common stock. Disc Medicine, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. The offering priced on January 22, 2025 and closed on January 24, 2025. Disc received approximately $259.3 in gross proceeds, before deducting underwriting discounts and commissions and offering expenses.

The WilmerHale team representing the underwriters consisted of Lisa Firenze, Ryan Brewer and Michelle Sidle, with assistance from Barish Ozdamar, with respect to intellectual property matters, and Meghan Walsh, with respect to tax matters.